Publication at Second Faculty of Medicine |
2013
Abstract
Osteosarcomas are rare diseases but are still the most common malignant tumours developing in bones and affect especially individuals younger than 20 years. After a long time, mifamurtide has recently been approved as a new drug indicated for the treatment of resected nonmetastatic osteo- sarcoma in children, adolescents and young adults after macroscopically radical surgical procedure.
It is used in combination with post surgery polychemotherapy in the dose of 2 mg/m 2 twice a week separated by at least 3 days for 12 weeks, and for another 24 weeks once weekly up to the maximum number of 48 infusions within 36 weeks.